Monopar Therapeutics revealed that it has obtained Human Research Ethics Committee (HREC) approval in Australia to initiate a Phase 1 clinical trial for its innovative radiopharmaceutical MNPR-101-Lu.

8.19-8.25 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

D&D Pharmatech begins Phase 2 trial for DD01, a long-lasting dual GLP-1/Glucagon receptor agonist, to assess its safety and efficacy in overweight/obese individuals with MASLD/MASH.

Aug 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) has had its second NDA accepted by NPMA for locally advanced or metastatic EGFR-mutant NSCLC.

IGC Pharma Broadens Medication Range to Include Metabolic Diseases with IGC-1A, a Possible New GLP-1 Agonist.

Azitra Reveals Initial Patient Screening and Enrollment Plans for Phase 1b ATR-12 Trial in Netherton Syndrome.

Innovo Therapeutics Inc. Unveils Phase 2 Clinical Data Highlighting the Breakthrough Effectiveness of INV-001 for Post-Thyroidectomy Scar Treatment.

The U.S. has approved RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) as an initial treatment without chemotherapy for patients with advanced lung cancer and EGFR mutations.

Sonnet BioTherapeutics Signs Clinical Collaboration for Investigator-Led, Funded Phase 1/2a Trial of SON-1210 with Chemotherapy in Pancreatic Cancer.

Aug 22nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

China's NMPA Grants Approval for PADCEV™ (Enfortumab Vedotin) to Treat Advanced or Metastatic Urothelial Cancer.